BioCentury
ARTICLE | Clinical News

ZS-9: Completed Phase III enrollment

July 21, 2014 7:00 AM UTC

ZS Pharma completed enrollment of 258 patients with hyperkalemia in the international Phase III ZS004 trial evaluating oral ZS-9. Patients are receiving 10 g ZS-9 thrice daily for 48 hours in the open...